Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cangene Corp announces approval by shareholders for acquisition by Emergent BioSolutions


Thursday, 13 Feb 2014 08:00am EST 

Cangene Corp:Says its shareholders have approved the previously announced acquisition by Emergent BioSolutions at a special meeting.Says acquisition will be implemented through a plan of arrangement under canadian law, under which cangene shareholders will receive $3.24 per share (C$3.57(1) per share) in cash, for an aggregate purchase price of $222 mln about C$245 mln(2)). 

Company Quote

21.31
0.1 +0.47%
22 Oct 2014